fexofenadine has been researched along with Hives in 58 studies
fexofenadine: a second generation antihistamine; metabolite of the antihistaminic drug terfenadine; structure in first source; RN refers to HCl
fexofenadine : A piperidine-based anti-histamine compound.
| Excerpt | Relevance | Reference |
|---|---|---|
| "H1-antihistamines are the first-line treatment of chronic idiopathic urticaria (CIU), but CIU is occasionally refractory to the conventional treatment doses." | 9.17 | Comparison of the efficacy of fexofenadine 120 and 240 mg/day on chronic idiopathic urticaria and histamine-induced skin responses in Japanese populations. ( Kabashima, K; Miyachi, Y; Nakahigashi, K; Tanizaki, H, 2013) |
| "The present study examined the impact of once-daily fexofenadine hydrochloride (HCl) 180 mg on health-related quality of life (HRQL) in subjects with chronic idiopathic urticaria (CIU)." | 9.12 | The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria. ( Harding, G; Leahy, MJ; Meeves, S; Shikiar, R; Spector, SL, 2007) |
| "The effect of 60 mg twice-daily fexofenadine HCl on health-related quality of life and productivity at work, in the classroom, and during daily activities in patients with moderate to severe chronic idiopathic urticaria symptoms was studied in two identical, 4-week, placebo-controlled, multicenter clinical trials." | 9.09 | Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria. ( Finn, AF; Schoenwetter, WF; Thompson, AK, 2000) |
| "Fexofenadine HCl significantly reduced pruritus severity, number of wheals, and interference with sleep and normal daily activities in patients with chronic urticaria compared with placebo." | 9.09 | Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. ( Mason, J; Nelson, HS; Reynolds, R, 2000) |
| "Fexofenadine HCl is well tolerated and is statistically superior to placebo in reducing signs and symptoms of CIU and in ameliorating interference with sleep and daily activities due to urticaria." | 9.09 | A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. ( Finn, AF; Fretwell, R; Kaplan, AP; Long, J; Qu, R, 1999) |
| "A 40-year-old male medical student presented with urticarial vasculitis secondary to occupational formaldehyde exposure." | 7.74 | Formaldehyde-induced urticarial vasculitis. ( Marshman, G; Pellizzari, M, 2007) |
| "fexofenadine is clinically effective in the treatment of seasonal allergic rhinitis and chronic idiopathic urticaria for which it is a suitable option for first-line therapy." | 7.70 | Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. ( Jarvis, B; Simpson, K, 2000) |
| "To evaluate the efficacy and safety of once-daily dosing of fexofenadine hydrochloride, 180 mg, on CIU." | 6.71 | Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study. ( Georges, G; Kaplan, AP; Liao, Y; Meeves, S; Spector, SL; Varghese, ST, 2005) |
| "Fexofenadine is a non-sedating antihistamine indicated for relieving symptoms from allergic conditions with a rapid onset of action without cardiotoxic risks." | 6.70 | Multicenter study of the efficacy and safety of fexofenadine 60 mg. twice daily in 108 Thai patients with chronic idiopathic urticaria. ( Aunhachoke, K; Charuwichitratana, S; Gherunpong, N; Gritiyarangsan, P; Janjumratsang, P; Jiamton, S; Korkij, W; Krisadapong, J; Kullavanijaya, P; Kulthanan, K; Kuntiranont, M; Sitakalin, C, 2001) |
| "Fexofenadine 180 mg is a new antihistamine that is effective in the treatment of chronic urticaria and that has a profile of side effects similar to placebo." | 6.70 | [Chronic idiopathic urticaria: effectiveness of fexofenadine. A double-blind, placebo controlled study with 21 patients]. ( Bircher, A; Degonda, M; Helbling, A; Pichler, WJ, 2002) |
| "Urticaria is a common clinical condition that gives a major concern for physicians and patients alike." | 5.56 | Efficacy of Fexofenadine in the Treatment of Chronic Idiopathic Urticaria. ( Akhter, F; Jahan, H; Nandi, AK, 2020) |
| " Fexofenadine given in the conventional dosage can prevent recurrences and represents a successful treatment measure when dealing with this peculiar form of solar urticaria." | 5.31 | Fixed solar urticaria to visible light successfully treated with fexofenadine. ( Bazex, J; Journé, F; Loche, E; Marguery, MC; Schwarze, HP, 2001) |
| "H1-antihistamines are the first-line treatment of chronic idiopathic urticaria (CIU), but CIU is occasionally refractory to the conventional treatment doses." | 5.17 | Comparison of the efficacy of fexofenadine 120 and 240 mg/day on chronic idiopathic urticaria and histamine-induced skin responses in Japanese populations. ( Kabashima, K; Miyachi, Y; Nakahigashi, K; Tanizaki, H, 2013) |
| "Nonsedating antihistamines (nsAHs) are recommended as first-line therapeutics for the treatment of mast cell-driven disorders, including allergic rhinitis and urticaria." | 5.14 | Suppression of histamine- and allergen-induced skin reactions: comparison of first- and second-generation antihistamines. ( dos Santos, RV; Lima, HC; Magerl, M; Mlynek, A, 2009) |
| "The present study examined the impact of once-daily fexofenadine hydrochloride (HCl) 180 mg on health-related quality of life (HRQL) in subjects with chronic idiopathic urticaria (CIU)." | 5.12 | The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria. ( Harding, G; Leahy, MJ; Meeves, S; Shikiar, R; Spector, SL, 2007) |
| "Levocetirizine is the active enantiomer of cetirizine, a potent drug with little metabolism widely used for allergic rhinitis and urticaria." | 5.10 | A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. ( DeVos, C; Grant, JA; Moulaert, B; Riethuisen, JM, 2002) |
| "Fexofenadine HCl is well tolerated and is statistically superior to placebo in reducing signs and symptoms of CIU and in ameliorating interference with sleep and daily activities due to urticaria." | 5.09 | A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. ( Finn, AF; Fretwell, R; Kaplan, AP; Long, J; Qu, R, 1999) |
| "Fexofenadine HCl significantly reduced pruritus severity, number of wheals, and interference with sleep and normal daily activities in patients with chronic urticaria compared with placebo." | 5.09 | Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. ( Mason, J; Nelson, HS; Reynolds, R, 2000) |
| "Pretreatment with fexofenadine during venom immunotherapy reduces local allergic reactions and generalized symptoms of the urticaria and angioedema type." | 5.09 | Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. ( Hari, Y; Müller, U; Reimers, A, 2000) |
| "The effect of 60 mg twice-daily fexofenadine HCl on health-related quality of life and productivity at work, in the classroom, and during daily activities in patients with moderate to severe chronic idiopathic urticaria symptoms was studied in two identical, 4-week, placebo-controlled, multicenter clinical trials." | 5.09 | Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria. ( Finn, AF; Schoenwetter, WF; Thompson, AK, 2000) |
| "Urticaria is mainly caused by mast cell-derived histamine through the histamine H(1) receptor." | 3.78 | Effects of bepotastine and fexofenadine on histamine-induced flare, wheal and itch. ( Fukuoka, M; Ikoma, A; Kabashima, K; Miyachi, Y; Tanizaki, H, 2012) |
| " We report a patient with urticaria due to ingestion of ebastine and fexofenadine." | 3.77 | Urticaria due to antihistamines. ( Laguna Martínez, JJ; Reaño Martos, M; Rojas Pérez-Ezquerra, P; Sánchez Morillas, L; Sanz, ML, 2011) |
| "A 40-year-old male medical student presented with urticarial vasculitis secondary to occupational formaldehyde exposure." | 3.74 | Formaldehyde-induced urticarial vasculitis. ( Marshman, G; Pellizzari, M, 2007) |
| "fexofenadine is clinically effective in the treatment of seasonal allergic rhinitis and chronic idiopathic urticaria for which it is a suitable option for first-line therapy." | 3.70 | Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. ( Jarvis, B; Simpson, K, 2000) |
| " However, the effect of long-term use of montelukast, a cystenil leukotriene receptor antagonist, on skin prick test hasn't been full elucidated." | 2.78 | The effect of montelukast on wheal reactions in skin prick tests: a double-blind-placebo-controlled randomized trial. ( Aydogan, M; Aydogmus, CY; Bulan, K; Siraneci, R, 2013) |
| "Levocetirizine was more inhibitory than fexofenadine on wheal, flare and pruritus (p < 0." | 2.78 | The inhibition by levocetirizine and fexofenadine of the histamine-induced wheal and flare response in healthy Caucasian and Japanese volunteers. ( Church, MK; Maurer, M; Schoepke, N, 2013) |
| "Fexofenadine (180 mg/d) was taken during the run-in period and subsequently throughout the study and follow-up as required." | 2.73 | Narrowband ultraviolet B phototherapy is beneficial in antihistamine-resistant symptomatic dermographism: a pilot study. ( Borzova, E; Grattan, CE; Konstantinou, GN; Leslie, KS; Rutherford, A, 2008) |
| "To evaluate the efficacy and safety of once-daily dosing of fexofenadine hydrochloride, 180 mg, on CIU." | 2.71 | Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study. ( Georges, G; Kaplan, AP; Liao, Y; Meeves, S; Spector, SL; Varghese, ST, 2005) |
| "Loratadine was statistically no different from placebo in terms of both overall wheal and flare suppression." | 2.71 | Suppression of the histamine-induced wheal and flare response by fexofenadine HCl 60 mg twice daily, loratadine 10 mg once daily and placebo in healthy Japanese volunteers. ( Boyle, J; Hindmarch, I; Johnsen, S; Meadows, R; Ridout, F, 2005) |
| "Fexofenadine is a non-sedating antihistamine indicated for relieving symptoms from allergic conditions with a rapid onset of action without cardiotoxic risks." | 2.70 | Multicenter study of the efficacy and safety of fexofenadine 60 mg. twice daily in 108 Thai patients with chronic idiopathic urticaria. ( Aunhachoke, K; Charuwichitratana, S; Gherunpong, N; Gritiyarangsan, P; Janjumratsang, P; Jiamton, S; Korkij, W; Krisadapong, J; Kullavanijaya, P; Kulthanan, K; Kuntiranont, M; Sitakalin, C, 2001) |
| "Fexofenadine 180 mg is a new antihistamine that is effective in the treatment of chronic urticaria and that has a profile of side effects similar to placebo." | 2.70 | [Chronic idiopathic urticaria: effectiveness of fexofenadine. A double-blind, placebo controlled study with 21 patients]. ( Bircher, A; Degonda, M; Helbling, A; Pichler, WJ, 2002) |
| "Ebastine was no better than placebo until 4 h, but was efficacious thereafter until 24 h." | 2.69 | A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects. ( Danielson, L; DeVos, C; Grant, JA; Rihoux, JP, 1999) |
| "Guidelines for the treatment of urticaria issued by Polish and international expert bodies were analyzed, along with the SPCs." | 2.49 | [Pharmacotherapy of urticaria--an analysis of the discrepancies between guidelines of expert bodies, registration documents and evidence for the effectiveness of drugs]. ( Plichta, D; Spiewak, R, 2013) |
| " No major cytochrome P450 inhibition has been reported with desloratadine, fexofenadine and levocetirizine, and the bioavailability of desloratadine is minimally affected by drugs interfering with transporter molecules." | 2.44 | Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. ( Devillier, P; Faisy, C; Roche, N, 2008) |
| "Urticaria is a common clinical condition that gives a major concern for physicians and patients alike." | 1.56 | Efficacy of Fexofenadine in the Treatment of Chronic Idiopathic Urticaria. ( Akhter, F; Jahan, H; Nandi, AK, 2020) |
| " In cases of failure, treatment was switched to omalizumab at doses of < 300 mg/month with incremental dosage increases as necessary (monthly dose range, 150-600 mg/month)." | 1.51 | Real-life experience in the treatment of solar urticaria: retrospective cohort study. ( Enk, CD; Hodak, E; Lapidoth, M; Levi, A; Mazor, S; Snast, I; Uvaidov, V, 2019) |
| " It is concluded that estimating in vivo receptor occupancy, which takes into account both the affinity of the drug for the receptor and its free plasma concentration, is a far better predictor for human pharmacodynamics and hence antihistamine potency, than considering in vitro affinity and plasmatic half-life only." | 1.33 | Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines. ( Baltes, E; Benedetti, MS; Chatelain, P; Gillard, M, 2005) |
| " Fexofenadine given in the conventional dosage can prevent recurrences and represents a successful treatment measure when dealing with this peculiar form of solar urticaria." | 1.31 | Fixed solar urticaria to visible light successfully treated with fexofenadine. ( Bazex, J; Journé, F; Loche, E; Marguery, MC; Schwarze, HP, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (6.90) | 18.2507 |
| 2000's | 37 (63.79) | 29.6817 |
| 2010's | 15 (25.86) | 24.3611 |
| 2020's | 2 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Jahan, H | 1 |
| Akhter, F | 1 |
| Nandi, AK | 1 |
| Hassan, K | 1 |
| Snast, I | 1 |
| Lapidoth, M | 1 |
| Uvaidov, V | 1 |
| Enk, CD | 2 |
| Mazor, S | 1 |
| Hodak, E | 1 |
| Levi, A | 2 |
| Hassoun, Y | 1 |
| Stevenson, MR | 1 |
| Bernstein, DI | 1 |
| Tanizaki, H | 3 |
| Nakahigashi, K | 1 |
| Miyachi, Y | 3 |
| Kabashima, K | 3 |
| Bulan, K | 1 |
| Aydogan, M | 1 |
| Siraneci, R | 1 |
| Aydogmus, CY | 1 |
| Plichta, D | 1 |
| Spiewak, R | 1 |
| Guo, A | 1 |
| Zhu, W | 1 |
| Zhang, C | 1 |
| Wen, S | 1 |
| Chen, X | 2 |
| Chen, M | 1 |
| Zhang, J | 1 |
| Su, J | 1 |
| Chen, W | 1 |
| Zhao, Y | 1 |
| Yan, S | 1 |
| He, Y | 1 |
| Liu, Z | 1 |
| Zhou, H | 1 |
| Li, J | 1 |
| Yamamoto, Y | 1 |
| Nakamizo, S | 1 |
| Otsuka, A | 1 |
| Hirohata, A | 1 |
| Yamaoka, T | 1 |
| Hayashi, M | 1 |
| Murota, H | 1 |
| Tani, M | 1 |
| Katayama, I | 1 |
| Hama, N | 1 |
| Shimomura, Y | 1 |
| Arinami, H | 1 |
| Maruyama, R | 1 |
| Abe, R | 1 |
| Izumi, N | 1 |
| Mizuguchi, H | 1 |
| Umehara, H | 1 |
| Ogino, S | 1 |
| Fukui, H | 1 |
| Borzova, E | 1 |
| Rutherford, A | 1 |
| Konstantinou, GN | 1 |
| Leslie, KS | 1 |
| Grattan, CE | 1 |
| Inomata, N | 1 |
| Tatewaki, S | 1 |
| Ikezawa, Z | 1 |
| dos Santos, RV | 1 |
| Magerl, M | 1 |
| Mlynek, A | 1 |
| Lima, HC | 1 |
| Shaikh, WA | 1 |
| Shaikh, SW | 1 |
| Sánchez Morillas, L | 1 |
| Rojas Pérez-Ezquerra, P | 1 |
| Reaño Martos, M | 1 |
| Sanz, ML | 1 |
| Laguna Martínez, JJ | 1 |
| Kamei, H | 1 |
| Isaji, A | 1 |
| Noda, Y | 1 |
| Ishikawa, K | 1 |
| Senzaki, K | 1 |
| Yamada, K | 1 |
| Sugiura, K | 1 |
| Tomita, Y | 1 |
| Nabeshima, T | 1 |
| Ikoma, A | 1 |
| Fukuoka, M | 1 |
| Church, MK | 2 |
| Maurer, M | 2 |
| Schoepke, N | 1 |
| Chowdhury, BA | 1 |
| Cassano, N | 1 |
| Filotico, R | 1 |
| D'Argento, V | 1 |
| Filieri, M | 1 |
| Coviello, C | 1 |
| Vena, G | 1 |
| Kawashima, M | 1 |
| Harada, S | 1 |
| Tango, T | 1 |
| Mekkes, JR | 1 |
| de Vries, HJ | 1 |
| Kammeyer, A | 1 |
| Duchateau, J | 1 |
| Heenen, M | 1 |
| Sternon, J | 1 |
| Handa, S | 1 |
| Dogra, S | 1 |
| Kumar, B | 1 |
| Roongapinun, S | 1 |
| Wajajamreon, S | 1 |
| Fooanant, S | 1 |
| Lennox, RD | 2 |
| Leahy, MJ | 2 |
| Purohit, A | 1 |
| N'Gom, AS | 1 |
| Deslandes, B | 1 |
| Pauli, G | 1 |
| Frossard, N | 1 |
| Shikiar, R | 2 |
| Harding, G | 2 |
| Leahy, M | 1 |
| Kaplan, AP | 2 |
| Spector, SL | 2 |
| Meeves, S | 2 |
| Liao, Y | 1 |
| Varghese, ST | 2 |
| Georges, G | 2 |
| Dhar, S | 1 |
| Boyle, J | 1 |
| Ridout, F | 1 |
| Meadows, R | 1 |
| Johnsen, S | 1 |
| Hindmarch, I | 1 |
| Gillard, M | 1 |
| Benedetti, MS | 1 |
| Chatelain, P | 1 |
| Baltes, E | 1 |
| Kłos, K | 2 |
| Kruszewski, J | 2 |
| Kruszewski, R | 1 |
| Sułek, K | 2 |
| Pellizzari, M | 1 |
| Marshman, G | 1 |
| Benhamou, AH | 1 |
| Vanini, G | 1 |
| Lantin, JP | 1 |
| Eigenmann, PA | 1 |
| Takahashi, H | 1 |
| Zhang, Y | 1 |
| Morita, E | 1 |
| Devillier, P | 1 |
| Roche, N | 1 |
| Faisy, C | 1 |
| De Vos, C | 1 |
| Mitchev, K | 1 |
| Pinelli, ME | 1 |
| Derde, MP | 1 |
| Boev, R | 1 |
| Paul, E | 1 |
| Markham, A | 1 |
| Wagstaff, AJ | 1 |
| Grant, JA | 2 |
| Danielson, L | 1 |
| Rihoux, JP | 1 |
| DeVos, C | 2 |
| Finn, AF | 2 |
| Fretwell, R | 1 |
| Qu, R | 1 |
| Long, J | 1 |
| Simpson, K | 1 |
| Jarvis, B | 1 |
| Nelson, HS | 1 |
| Reynolds, R | 1 |
| Mason, J | 1 |
| Reimers, A | 1 |
| Hari, Y | 1 |
| Müller, U | 1 |
| Thompson, AK | 1 |
| Schoenwetter, WF | 1 |
| Schwarze, HP | 1 |
| Marguery, MC | 1 |
| Journé, F | 1 |
| Loche, E | 1 |
| Bazex, J | 1 |
| Nettis, E | 1 |
| Dambra, P | 1 |
| D'Oronzio, L | 1 |
| Loria, MP | 1 |
| Ferrannini, A | 1 |
| Tursi, A | 1 |
| Amichai, B | 1 |
| Grunwald, MH | 1 |
| Brenner, L | 1 |
| Kulthanan, K | 1 |
| Gritiyarangsan, P | 1 |
| Sitakalin, C | 1 |
| Charuwichitratana, S | 1 |
| Korkij, W | 1 |
| Aunhachoke, K | 1 |
| Janjumratsang, P | 1 |
| Jiamton, S | 1 |
| Kuntiranont, M | 1 |
| Krisadapong, J | 1 |
| Gherunpong, N | 1 |
| Kullavanijaya, P | 1 |
| Riethuisen, JM | 1 |
| Moulaert, B | 1 |
| Degonda, M | 1 |
| Pichler, WJ | 1 |
| Bircher, A | 1 |
| Helbling, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Observational Study of the Prevalence of Antihistamine Responsive Gastrointestinal Symptoms in Patients Diagnosed With Irritable Bowel Syndrome With Diarrhea[NCT04612803] | 100 participants (Anticipated) | Observational | 2020-11-15 | Not yet recruiting | |||
| Comparison of Efficacy and Consistency of Action of Levocetirizine 5 mg Once Daily With Fexofenadine 60 mg Twice Daily in the Histamine Induced Wheal, Flare and Itch Response[NCT01586091] | Phase 4 | 18 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Flaire diameter was measured with a transparent ruler as the mean of the largest diameter and the diameter at right angles to this. (NCT01586091)
Timeframe: 24 hours per treatment
| Intervention | mm (Mean) |
|---|---|
| Placebo | 69.4 |
| Levocetirizin | 20.4 |
| Fexofenadine | 39.9 |
"We measured drug concentrations and various aspects of skin provocation testing such as itch intensity and wheal size. Measurements made at each time point were as followed: Pruritus was assessed every 30 s for 10 min after SPT using a visual analogue scale (VAS) score with a 0 and 100 at the two ex- tremes of an unmarked 100 mm line with higher values indicating greater puritus. The mean VAS for each 10 min was calculated and used as a primary end Point." (NCT01586091)
Timeframe: up to 10 minutes after skin prick test performed 24 hours after drug administration
| Intervention | mm (Mean) |
|---|---|
| Levocetirizin | 11.5 |
| Fexofenadine | 25.4 |
| Placebo | 46.0 |
Wheal volume was measured by a non-contact three dimensional measurement system (PRIMOS contact, GFM Messtechnik GmbH, Teltow, Germany). (NCT01586091)
Timeframe: 24 hours per treatment
| Intervention | cm3 (Mean) |
|---|---|
| Placebo | 174.6 |
| Levocetirizin | 35.2 |
| Fexofenadine | 106.3 |
7 reviews available for fexofenadine and Hives
| Article | Year |
|---|---|
[Pharmacotherapy of urticaria--an analysis of the discrepancies between guidelines of expert bodies, registration documents and evidence for the effectiveness of drugs].
Topics: Administration, Oral; Administration, Topical; Anti-Allergic Agents; Benzimidazoles; Cetirizine; Glu | 2013 |
H(1)-antihistamines and urticaria: how can we predict the best drug for our patient?
Topics: Anti-Allergic Agents; Cetirizine; Histamine; Histamine H1 Antagonists, Non-Sedating; Humans; Loratad | 2012 |
Review of fexofenadine in the treatment of chronic idiopathic urticaria.
Topics: Anti-Allergic Agents; Asia; Chronic Disease; Humans; North America; Terfenadine; Urticaria | 2002 |
[H1 histamine antagonists].
Topics: Acetates; Anti-Allergic Agents; Cetirizine; Chemistry, Pharmaceutical; Histamine H1 Antagonists; Hum | 2003 |
Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.
Topics: Cetirizine; Drug Interactions; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Rhinitis, | 2008 |
Fexofenadine.
Topics: Animals; Histamine Antagonists; Humans; Rhinitis, Allergic, Seasonal; Terfenadine; Urticaria | 1998 |
Fexofenadine hydrochloride--a new anti-histaminic drug.
Topics: Chronic Disease; Clinical Trials as Topic; Drug Interactions; Histamine H1 Antagonists; Humans; Pati | 2001 |
27 trials available for fexofenadine and Hives
| Article | Year |
|---|---|
Comparison of the efficacy of fexofenadine 120 and 240 mg/day on chronic idiopathic urticaria and histamine-induced skin responses in Japanese populations.
Topics: Adult; Chronic Disease; Cross-Over Studies; Double-Blind Method; Female; Histamine; Histamine H1 Ant | 2013 |
The effect of montelukast on wheal reactions in skin prick tests: a double-blind-placebo-controlled randomized trial.
Topics: Acetates; Allergens; Animals; Asthma; Chi-Square Distribution; Child; Cyclopropanes; Dose-Response R | 2013 |
Association of FCER1A genetic polymorphisms with risk for chronic spontaneous urticaria and efficacy of nonsedating H1-antihistamines in Chinese patients.
Topics: Adult; Asian People; Benzimidazoles; China; Female; Genotyping Techniques; Histamine H1 Antagonists, | 2015 |
Comparison of the efficacy of olopatadine and fexofenadine in chronic idiopathic urticaria patients: a crossover study.
Topics: Adult; Anti-Allergic Agents; Chronic Disease; Cross-Over Studies; Dibenzoxepins; Female; Histamine H | 2015 |
Narrowband ultraviolet B phototherapy is beneficial in antihistamine-resistant symptomatic dermographism: a pilot study.
Topics: Adult; Drug Resistance; Female; Histamine H1 Antagonists; Humans; Male; Pilot Projects; Prospective | 2008 |
Suppression of histamine- and allergen-induced skin reactions: comparison of first- and second-generation antihistamines.
Topics: Adult; Allergens; Animals; Dermatophagoides pteronyssinus; Dibenzazepines; Double-Blind Method; Fema | 2009 |
Effects of single therapeutic doses of promethazine, fexofenadine and olopatadine on psychomotor function and histamine-induced wheal- and flare-responses: a randomized double-blind, placebo-controlled study in healthy volunteers.
Topics: Adolescent; Dibenzoxepins; Double-Blind Method; Female; Histamine H1 Antagonists; Humans; Male; Olop | 2012 |
The inhibition by levocetirizine and fexofenadine of the histamine-induced wheal and flare response in healthy Caucasian and Japanese volunteers.
Topics: Adult; Asian People; Cetirizine; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2013 |
Comparative efficacy of cetirizine and fexofenadine in the treatment of chronic idiopathic urticaria.
Topics: Adolescent; Adult; Aged; Cetirizine; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Seda | 2004 |
Comparative efficacy of wheal-and-flare suppression among various non-sedating antihistamines and the pharmacologic insights to their efficacy.
Topics: Adolescent; Adult; Cetirizine; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; M | 2004 |
Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of life.
Topics: Chronic Disease; Dermatology; Dose-Response Relationship, Drug; Double-Blind Method; Histamine H1 An | 2004 |
Similar rapid onset of action and magnitude of effect of fexofenadine and cetirizine as assessed by inhibition of histamine-induced wheal-and-flare reaction.
Topics: Adolescent; Adult; Cetirizine; Cross-Over Studies; Female; Histamine; Histamine H1 Antagonists; Huma | 2004 |
Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Child; Chronic Disease; Double-Blind Method; Female; Humans; Male; Terfenadine; Urticari | 2005 |
Suppression of the histamine-induced wheal and flare response by fexofenadine HCl 60 mg twice daily, loratadine 10 mg once daily and placebo in healthy Japanese volunteers.
Topics: Adult; Drug Therapy, Combination; Female; Histamine H1 Antagonists; Humans; Japan; Loratadine; Male; | 2005 |
[The effect of 5-days of cetirizine, desloratadine, fexofenadine 120 and 180 mg, levocetirizine, loratadine treatment on the histamine-induced skin reaction and skin blood flow--a randomized, double-blind, placebo controlled trial].
Topics: Administration, Oral; Adult; Cetirizine; Double-Blind Method; Drug Administration Schedule; Histamin | 2006 |
[Inhibition of histamine-induced wheel after a recommended single dose administration of 10 mg cetirizine, 5 mg desloratadine, 120 i 180 mg fexofenadine, 5 mg levocetirizine and 10 mg loratadine--a randomized, double-blind, placebo controlled trial].
Topics: Administration, Oral; Adult; Cetirizine; Double-Blind Method; Histamine; Histamine H1 Antagonists, N | 2006 |
The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria.
Topics: Adolescent; Chronic Disease; Double-Blind Method; Efficiency; Female; Histamine H1 Antagonists, Non- | 2007 |
Evaluation of the antihistamine effects of olopatadine, cetirizine and fexofenadine during a 24 h period: a double-blind, randomized, crossover, placebo-controlled comparison in skin responses induced by histamine iontophoresis.
Topics: Adult; Cetirizine; Cross-Over Studies; Dibenzoxepins; Dose-Response Relationship, Drug; Double-Blind | 2008 |
A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects.
Topics: Adult; Butyrophenones; Cetirizine; Cross-Over Studies; Dibenzazepines; Double-Blind Method; Histamin | 1999 |
A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria.
Topics: Adolescent; Adult; Aged; Child; Chronic Disease; Double-Blind Method; Female; Histamine H1 Antagonis | 1999 |
Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Child; Chronic Disease; Disorders of Excessive Somnol | 2000 |
Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Angioedema; Anti-Allergic Agents; Bee Venoms; Double-Blind Method; Drug Therapy, | 2000 |
Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria.
Topics: Adolescent; Adult; Aged; Chronic Disease; Female; Histamine H1 Antagonists; Humans; Male; Middle Age | 2000 |
Comparison of montelukast and fexofenadine for chronic idiopathic urticaria.
Topics: Acetates; Adult; Aged; Chronic Disease; Cyclopropanes; Double-Blind Method; Female; Histamine H1 Ant | 2001 |
Multicenter study of the efficacy and safety of fexofenadine 60 mg. twice daily in 108 Thai patients with chronic idiopathic urticaria.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chronic Disease; Female; Histamine H1 Antagonists; Human | 2001 |
A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects.
Topics: Adult; Benzimidazoles; Butyrophenones; Cetirizine; Cross-Over Studies; Double-Blind Method; Histamin | 2002 |
[Chronic idiopathic urticaria: effectiveness of fexofenadine. A double-blind, placebo controlled study with 21 patients].
Topics: Adult; Aged; Anti-Allergic Agents; Chronic Disease; Double-Blind Method; Female; Humans; Male; Middl | 2002 |
24 other studies available for fexofenadine and Hives
| Article | Year |
|---|---|
Efficacy of Fexofenadine in the Treatment of Chronic Idiopathic Urticaria.
Topics: Adolescent; Bangladesh; Chronic Disease; Chronic Urticaria; Double-Blind Method; Humans; Terfenadine | 2020 |
Urticaria and angioedema as a prodromal cutaneous manifestation of SARS-CoV-2 (COVID-19) infection.
Topics: Angioedema; Anti-Allergic Agents; Betacoronavirus; Chlorpheniramine; Coronavirus Infections; COVID-1 | 2020 |
Real-life experience in the treatment of solar urticaria: retrospective cohort study.
Topics: Acetates; Adolescent; Adult; Aged; Anti-Allergic Agents; Cetirizine; Child; Cohort Studies; Cyclopro | 2019 |
Idiopathic postprandial diarrhea responsive to antihistamines.
Topics: Adult; Angioedema; Cetirizine; Diarrhea; Famotidine; Female; Food Hypersensitivity; Histamine Antago | 2019 |
Treatment of solar urticaria using antihistamine and leukotriene receptor antagonist combinations tailored to disease severity.
Topics: Acetates; Adolescent; Adult; Cetirizine; Child; Child, Preschool; Cyclopropanes; Drug Therapy, Combi | 2015 |
Unique case of postural cholinergic urticaria induced by a standing position.
Topics: Acetylcholine; Adolescent; Diphenhydramine; Humans; Male; Posture; Terfenadine; Urticaria | 2016 |
Localized heat urticaria: Positive reaction of preheated autologous serum skin test.
Topics: Anaphylaxis; Chlorpheniramine; Desensitization, Immunologic; Drug Therapy, Combination; Histamine H1 | 2016 |
Analysis of disease-dependent sedative profiles of H(1)-antihistamines by large-scale surveillance using the visual analog scale.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asthma; Butyrophenones; Cetirizine; Child; Chlorpheniram | 2008 |
Multiple H1-antihistamine-induced urticaria.
Topics: Administration, Oral; Adult; Drug Eruptions; Female; Histamine; Histamine H1 Antagonists; Humans; Im | 2009 |
Allergies in India: a study on medication compliance.
Topics: Adolescent; Adult; Anti-Allergic Agents; Asthma; Bronchodilator Agents; Budesonide; Child; Ethanolam | 2009 |
Urticaria due to antihistamines.
Topics: Administration, Oral; Butyrophenones; Diagnosis, Differential; Drug Hypersensitivity; Female; Histam | 2011 |
Effects of bepotastine and fexofenadine on histamine-induced flare, wheal and itch.
Topics: Adult; Female; Histamine; Histamine H1 Antagonists, Non-Sedating; Humans; Male; Piperidines; Pruritu | 2012 |
Chronic urticaria and angioedema.
Topics: Angioedema; Chronic Disease; Histamine H1 Antagonists; Humans; Terfenadine; Urticaria | 2002 |
In vivo anti-inflammatory effects of fexofenadine in chronic idiopathic urticaria.
Topics: Adolescent; Adult; Biopsy, Needle; Case-Control Studies; Chronic Disease; Culture Techniques; E-Sele | 2002 |
Solar urticaria induced by infrared radiation.
Topics: Female; Histamine H1 Antagonists; Humans; Infrared Rays; Middle Aged; PUVA Therapy; Terfenadine; Urt | 2003 |
Minimal important difference (MID) of the Dermatology Life Quality Index (DLQI): results from patients with chronic idiopathic urticaria.
Topics: Adolescent; Adult; Aged; Child; Chronic Disease; Clinical Trials, Phase III as Topic; Data Interpret | 2005 |
Assessing the therapeutic benefits of antihistamines for the treatment of chronic idiopathic urticaria--a requirement for well-designed comparative clinical studies.
Topics: Cetirizine; Histamine H1 Antagonists, Non-Sedating; Humans; Terfenadine; Treatment Outcome; Urticari | 2005 |
Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines.
Topics: Animals; Cetirizine; CHO Cells; Cricetinae; Cricetulus; Histamine H1 Antagonists; Humans; Loratadine | 2005 |
Formaldehyde-induced urticarial vasculitis.
Topics: Adult; Drug Therapy, Combination; Formaldehyde; Glucocorticoids; Histamine H1 Antagonists, Non-Sedat | 2007 |
Antihistamine and sodium cromoglycate medication for food cold water exercise-induced anaphylaxis.
Topics: Adolescent; Anaphylaxis; Anti-Asthmatic Agents; Cold Temperature; Cromolyn Sodium; Drug Therapy, Com | 2007 |
Non-interventional study comparing treatment satisfaction in patients treated with antihistamines.
Topics: Activities of Daily Living; Administration, Oral; Adult; Aged; Aged, 80 and over; Cetirizine; Child; | 2008 |
[Further development of terfenadine].
Topics: Clinical Trials as Topic; Histamine Antagonists; Histamine H1 Antagonists; Humans; Hypersensitivity, | 1997 |
Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria.
Topics: Administration, Oral; Adolescent; Adult; Anti-Allergic Agents; Chronic Disease; Dose-Response Relati | 2000 |
Fixed solar urticaria to visible light successfully treated with fexofenadine.
Topics: Anti-Allergic Agents; Female; Humans; Middle Aged; Sunlight; Terfenadine; Ultraviolet Rays; Urticari | 2001 |